Nieto, Karina

Abstract Background Geometric uncertainties in high‐dose‐rate brachytherapy, including applicator displacement, catheter deflection, and interstitial needle spread, produce dose deviations that are patient and plan specific. Unlike external beam radiotherapy, where robustness evaluation frameworks are increasingly standardized, high dose rate brachytherapy lacks a normalized aggregate metric for quantifying plan sensitivity to geometric perturbations. Purpose To define a bounded, dimensionless robustness index for per‐fraction evaluation of high dose rate brachytherapy plans that is normalized to clinically meaningful dose‐limit constraints, incorporates dose‐dependent penalty sensitivity, and provides both a full‐scenario severity measure and a dose‐threshold‐filtered variant. Methods Geometric perturbation scenarios (translations, rotations, radial expansion/contraction, catheter deflection, and combined modes) are applied to source dwell positions. For each organ at risk, a convex‐transformed, constraint‐normalized penalty quantifies the fraction of the remaining margin to the dose‐limit constraint consumed per scenario. For target volumes, a prescription‐normalized piecewise penalty captures under‐coverage and excessive dose escalation. The Robustness Index is defined as one minus the mean scenario penalty, yielding a value in [0,1]. Results The framework produces structure‐independent, interpretable indices where a Robustness Index indicates that scenarios consume on average only 10% of the normalized remaining margin to the dose‐limit constraint. A threshold‐filtered variant evaluates robustness among only those scenarios that exceed a clinically specified dose level. Conclusions The proposed robustness index provides a standardized, clinically anchored metric for high dose rate brachytherapy plan evaluation under geometric uncertainty, complementing existing dose volume histogram based reporting with a single interpretable number per structure.

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cervical Cancer provide diagnostic workup, staging, and various treatment recommendations for cervical cancer based on clinical and surgical staging. This selection from the NCCN Guidelines for cervical cancer specifically focuses on diagnosis and workup, principles of staging and surgery, and primary treatment recommendations for early-stage and advanced disease and provides a detailed overview of systemic therapy recommendations for cervical cancer.

The NCCN Guidelines for Uterine Neoplasms provide recommendations for diagnostic workup, clinical staging, and treatment options for patients with endometrial cancer and uterine sarcoma. The NCCN Cervical Uterine Panel meets at least annually to review comments from reviewers within their institutions; examine relevant new data from publications, abstracts, and recent FDA approvals; and reevaluate and update recommendations. These NCCN Guidelines Insights summarize the panel’s deliberations on the new FIGO 2023 staging system and updates on the new systemic therapy recommendations for the management of endometrial cancer.